Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.
Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation
ROLLA, Roberta;MARINO, Paolo;BELLOMO, Giorgio;DE LUCA, GIUSEPPE
2016-01-01
Abstract
Residual high-on treatment platelet reactivity (HRPR) predicts outcomes and major cardiovascular events. Ticagrelor has provided pharmacological and clinical evidence of more predictable and more potent antiplatelet effect as compared to clopidogrel. However, so far, few data have investigated the prevalence and predictors of HRPR in unselected patients treated with ticagrelor, that is therefore the aim of the current study.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
57..pdf
file disponibile agli utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
DRM non definito
Dimensione
521.17 kB
Formato
Adobe PDF
|
521.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
